8-K: Ekso Bionics Announces Reverse Stock Split, Adjusts Effective Date to June 2, 2025

Ekso Bionics has updated the effective date of its previously approved 1-for-15 reverse stock split to June 2, 2025, to increase its stock price and regain Nasdaq compliance.

Summary

• Ekso Bionics announced a change in the effective date of its reverse stock split.
• The reverse stock split, at a ratio of 1-for-15, will now be effective on June 2, 2025, at 12:01 a.m. PT.
• The company's stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol EKSO on June 2, 2025.
• The new CUSIP number for the common stock will be 282644 400.
• The reverse stock split will reduce the number of outstanding shares from approximately 35.5 million to approximately 2.4 million.
• The primary purpose of the reverse stock split is to increase the per-share trading price to meet Nasdaq's minimum bid price requirement.
• The company received a notice from Nasdaq on December 12, 2024, for failing to meet the minimum bid price requirement.
• No fractional shares will be issued; any fractional shares will be rounded up to the next whole share.
• The reverse stock split will affect all issued and outstanding shares, stock options, warrants, and restricted stock units.
• The reverse stock split will not change the par value of the shares or significantly alter any stockholder's percentage interest in the company's equity.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the reverse stock split is intended to improve the company's stock price and Nasdaq compliance, it is also a sign of past stock performance issues. The company's future success depends on various factors, including market acceptance of its products and competition.

Positives

• The reverse stock split aims to increase the stock price, potentially making the company more attractive to investors.
• Regaining compliance with Nasdaq listing requirements could improve investor confidence.
• Rounding up fractional shares to the next whole share is beneficial for shareholders who would otherwise receive fractional shares.

Negatives

• The reverse stock split is a consequence of failing to meet Nasdaq's minimum bid price requirement, indicating past stock performance issues.
• Existing shareholders will own fewer shares after the split, although their percentage ownership remains largely unchanged.
• The company had to delay the effective date of the reverse stock split.

Risks

• There is no guarantee that the reverse stock split will successfully increase the stock price or maintain Nasdaq compliance.
• The company's future performance is subject to various risks and uncertainties, including market acceptance of its products and competition.
• Failure to maintain Nasdaq listing could result in delisting, which would negatively impact the stock's liquidity and value.

Future Outlook

The company expects the reverse stock split to increase its stock price and help regain compliance with Nasdaq's minimum bid price requirement. However, the company's future performance is subject to various risks and uncertainties.

Management Comments

• Ekso Bionics is implementing a reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time.
• The reverse stock split was approved by the Company's stockholders at a special meeting held on May 16, 2025, and is primarily intended to raise the per share trading price of the Company's common stock.

Industry Context

Reverse stock splits are often used by companies facing delisting from exchanges due to low stock prices. This action is intended to make the stock more attractive to investors and regain compliance with listing requirements. Other companies in similar situations may consider similar actions.

Comparison to Industry Standards

• Reverse stock splits are a relatively common strategy for companies facing delisting from exchanges due to low stock prices.
• Many companies in the biotech and medical device industries, particularly those with speculative or developmental products, have used reverse stock splits to maintain listing compliance.
• For example, companies like Titan Pharmaceuticals and Cytokinetics have previously implemented reverse stock splits to boost their share prices and remain on the Nasdaq.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership should remain largely unchanged.
• The reverse stock split aims to improve investor confidence by increasing the stock price and maintaining Nasdaq compliance.
• Employees' stock options and restricted stock units will be adjusted to reflect the reverse stock split.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on June 2, 2025.
• Stockholders holding share certificates may request information from VStock Transfer, LLC, regarding the process for exchanging certificates.

Key Dates

Keywords

reverse stock split, Ekso Bionics, Nasdaq, minimum bid price, compliance, EKSO, stock price